Natco, Watson deal

Natco granted Watson exclusive, U.S. rights to develop and commercialize a generic version of lenalidomide 5, 10, 15 and 25 mg tablets. Natco submitted an ANDA in August and Watson will assume responsibility for regulatory, legal and commercial expenses. The partners will share net profits on sales. Further terms were not disclosed. ...